An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Open accessAbstract
Tumour cells, with stem-like properties, are highly aggressive and often show drug resistance. Here, we reveal that integrin α(v)β₃ serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in mice bearing patient-derived tumour xenografts or in clinical specimens from lung cancer patients who had progressed on erlotinib. Mechanistically, α(v)β₃, in the unliganded state, recruits KRAS and RalB to the tumour cell plasma membrane, leading to the activation of TBK1 and NF-κB. In fact, α(v)β₃ expression and the resulting KRAS-RalB-NF-κB pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance. Pharmacological targeting of this pathway with bortezomib reversed both tumour stemness and erlotinib resistance. These findings not only identify α(v)β₃ as a marker/driver of carcinoma stemness but also reveal a therapeutic strategy to sensitize such tumours to RTK inhibition.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Integrin αvβ3 can induce apoptosis, tumor progression, and tumor stemness in an anchorage-independent manner.
“In fact, integrin αvβ3 can induce apoptosis (Stupack et al., 2001), tumor progression (Desgrosellier et al., 2009), and tumor stemness (Seguin et al., 2014) in an anchorage-independent manner.”
From Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway (2017) · cites this paper as Seguin et al., 2014
Integrins can mediate signaling cascades independent of ligand binding.
“Interestingly, integrins can also mediate signaling cascades independent of ligand binding.”
From Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway (2017) · cites this paper as Seguin et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2748 · Cited by 3,721 · see citing works
Self-citationTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · see citing works
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J., & Lindeman, G. (2008) · Nature Reviews. Cancer · doi:10.1038/nrc2499 · Cited by 3,562 · see citing works
Requirement of Vascular Integrin α <sub>v</sub> β <sub>3</sub> for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020 · see citing works
Self-citationHermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M. O., Bruns, C. J., & Heeschen, C. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,898 · see citing works
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · see citing works
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,063 · see citing works
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutiérrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A. C., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794 · see citing works
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · see citing works
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · see citing works
Cancer stem cells: impact, heterogeneity, and uncertainty
Magee, J. A., Piskounova, E., & Morrison, S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.003 · Cited by 1,137 · see citing works
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
Bhat, K., Balasubramaniyan, V., Vaillant, B. D., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L. E., James, J. D., Goodman, L. D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.001 · Cited by 1,110 · see citing works
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A. S., Stewart, D. J., Hicks, M. E., Erasmus, J. J., Gupta, S. K., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 888 · see citing works
Self-citationGata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation
Asselin-Labat, M.-L., Sutherland, K. D., Barker, H., Thomas, R., Shackleton, M., Forrest, N. C., Hartley, L., Robb, L., Grosveld, F. G., van der Wees, J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1530 · Cited by 840 · see citing works
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
Brooks, P. C., Strömblad, S., Klemke, R. L., Visscher, D. W., Sarkar, F. H., & Cheresh, D. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118227 · Cited by 828 · see citing works
Self-citationCancer stem cells: The challenges ahead
Medema, J. P. (2013) · Nature Cell Biology · doi:10.1038/ncb2717 · Cited by 740 · see citing works
Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706 · see citing works
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · see citing works
Cheresh, D. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6471 · Cited by 569 · see citing works
Self-citationAntibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427 · see citing works
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396 · see citing works
The developing cancer stem-cell model: clinical challenges and opportunities
Vermeulen, L., Melo, F. D. S. E., Richel, D. J., & Medema, J. P. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70257-1 · Cited by 389 · see citing works
Chien, Y., Kim, S., Bumeister, R., Loo, Y., Kwon, S. W., Johnson, C., Balakireva, M. G., Roméo, Y., Kopelovich, L., Gale, M., et al. (2006) · Cell · doi:10.1016/j.cell.2006.08.034 · Cited by 367 · see citing works
Galectin-3 – A jack-of-all-trades in cancer
Newlaczyl, A. U., & Yu, L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.003 · Cited by 363 · see citing works
Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response
Markowska, A. I., Liu, F., & Panjwani, N. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20090121 · Cited by 330 · see citing works
Vaillant, F., Asselin-Labat, M.-L., Shackleton, M. J., Forrest, N. C., Lindeman, G. J., & Visvader, J. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1949 · Cited by 315 · see citing works
An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression
Desgrosellier, J. S., Barnes, L. A., Shields, D. J., Huang, M., Lau, S. K., Prévost, N., Tarin, D., Shattil, S. J., & Cheresh, D. A. (2009) · Nature Medicine · doi:10.1038/nm.2009 · Cited by 293 · see citing works
Self-citationTumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone
Sloan, E. K., Pouliot, N., Stanley, K. L., Chia, J., Moseley, J. M., Hards, D. K., & Anderson, R. L. (2006) · Breast Cancer Research · doi:10.1186/bcr1398 · Cited by 276 · see citing works
Shien, K., Toyooka, S., Yamamoto, H., Soh, J., Jida, M., Thu, K. L., Hashida, S., Maki, Y., Ichihara, E., Asano, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4136 · Cited by 269 · see citing works
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Kumar, M. S., Hancock, D. C., Molina‐Arcas, M., Steckel, M., East, P., Diefenbacher, M. E., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 264 · see citing works
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling
Rajasekhar, V. K., Studer, L., Gerald, W. L., Socci, N. D., & Scher, H. I. (2011) · Nature Communications · doi:10.1038/ncomms1159 · Cited by 260 · see citing works
Ras trafficking, localization and compartmentalized signalling
Prior, I. A., & Hancock, J. F. (2011) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2011.09.002 · Cited by 242 · see citing works
Integrin Connections Map: To Infinity and Beyond
Martin, K. H., Slack, J. K., Boerner, S. A., Martin, C. C., & Parsons, J. T. (2002) · Science · doi:10.1126/science.296.5573.1652 · Cited by 235 · see citing works
Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone
Pécheur, I., Peyruchaud, O., Serre, C., Guglielmi, J., Voland, C., Bourre, F., Margue, C., Cohen-Solal, M. E., Buffet, A., Kieffer, N., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0911fje · Cited by 223 · see citing works
Retinoid signaling regulates breast cancer stem cell differentiation
Ginestier, C., Wicinski, J., Cervera, N., Monville, F., Finetti, P., Bertucci, F., Wicha, M. S., Birnbaum, D., & Charafe‐Jauffret, E. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9761 · Cited by 217 · see citing works
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H. N., Nilsson, M. B., Oborn, C. J., Park, Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 160 · see citing works
Self-citationLo, P.-K., Kanojia, D., Liu, X., Singh, U. P., Berger, F. G., Wang, Q., & Chen, H. (2011) · Oncogene · doi:10.1038/onc.2011.439 · Cited by 160 · see citing works
Zheng, Y., de la Cruz, C. C., Sayles, L. C., Alleyne-Chin, C., Vaka, D., Knaak, T. D., Bigos, M., Xu, Y., Hoang, C. D., Shrager, J. B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.021 · Cited by 154 · see citing works
Scheppke, L., Murphy, E. A., Zarpellon, A., Hofmann, J. J., Merkulova, A. A., Shields, D. J., Weis, S. M., Byzova, T. V., Ruggeri, Z. M., Iruela‐Arispe, M. L., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348706 · Cited by 144 · see citing works
Self-citationMiller, P., Al-Shahrour, F., Hartwell, K. A., Chu, L., Järås, M., Puram, R. V., Puissant, A., Callahan, K., Ashton, J., McConkey, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.004 · Cited by 144 · see citing works
K-Ras Nanoclustering Is Subverted by Overexpression of the Scaffold Protein Galectin-3
Shalom‐Feuerstein, R., Plowman, S. J., Rotblat, B., Ariotti, N., Tian, T., Hancock, J. F., & Kloog, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1117 · Cited by 141 · see citing works
Hypoxia-inducible Factor Regulates αvβ3 Integrin Cell Surface Expression
Dahl, K. D. C., Robertson, S. E., Weaver, V. M., & Simon, M. C. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1082 · Cited by 134 · see citing works
Takayama, S., Ishii, S., Ikeda, T., Masamura, S., Doi, M., & Kitajima, M. (2005) · PubMed · Cited by 134 · see citing works
Targeting breast cancer stem cells.
Liu, S.-L., & Wicha, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 131 · see citing works
Knowles, L. M., Gurski, L. A., Engel, C., Gnarra, J. R., Maranchie, J. K., & Pilch, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0602 · Cited by 110 · see citing works
The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma
Rothhammer-Hampl, T., Hahne, J. C., Florin, A., Poser, I., Soncin, F., Wernert, N., & Bosserhoff, A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3337-8 · Cited by 108 · see citing works
β3 Integrin Expression in Melanoma Predicts Subsequent Metastasis
Hieken, T. J., Farolan, M. J., Ronan, S. G., Shilkaitis, A. L., Wild, L., & Gupta, T. K. D. (1996) · Journal of Surgical Research · doi:10.1006/jsre.1996.0242 · Cited by 104 · see citing works
Hamada, J., Omatsu, T., Okada, F., Furuuchi, K., Okubo, Y., Takahashi, Y., Tada, M., Miyazaki, Y. J., Taniguchi, Y., Shirato, H., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1357 · Cited by 80 · see citing works
Cancer stem cells, tumor dormancy, and metastasis
Patel, P. R., & Chen, E. I. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00125 · Cited by 78 · see citing works
A MEK-independent role for CRAF in mitosis and tumor progression
Mielgo, A., Seguin, L., Huang, M., Camargo, M. F., Anand, S., Franovic, A., Weis, S. M., Advani, S. J., Murphy, E. A., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2464 · Cited by 67 · see citing works
Self-citationEvellin, S., Galvagni, F., Zippo, A., Neri, F., Orlandini, M., Incarnato, D., Dettori, D., Neubauer, S., Kessler, H., Wagner, E. F., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01054-12 · Cited by 52 · see citing works
Metastatic potential of tumor-initiating cells in solid tumors
Amit, S. A. (2010) · Frontiers in bioscience · doi:10.2741/3831 · Cited by 38 · see citing works
ATM-Mediated DNA Damage Signals Mediate Immune Escape through Integrin-αvβ3–Dependent Mechanisms
Jinushi, M., Chiba, S., Baghdadi, M., Kinoshita, I., Dosaka‐Akita, H., Ito, K., Yoshiyama, H., Yagita∥, H., Uede, T., & Takaoka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2028 · Cited by 27 · see citing works
CD61 enriches long-term repopulating hematopoietic stem cells
Umemoto, T., Yamato, M., Shiratsuchi, Y., Terasawa, M., Yang, J., Nishida, K., Kobayashi, Y., & Okano, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.168 · Cited by 26 · see citing works
Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR
Workman, P., & Clarke, P. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.020 · Cited by 22 · see citing works
Cancer stem cell in the progression and therapy of pancreatic cancer
Xu, L. (2013) · Frontiers in bioscience · doi:10.2741/4143 · Cited by 21 · see citing works
Human Integrin β3 Gene Expression: Evidence for a Megakaryocytic Cell-Specific cis-Acting Element
Jin, Y. S., Wilhide, C. C., Dang, C. V., Li, L., Li, S.-X., Villa‐Garcia, M., & Bray, P. F. (1998) · Blood · doi:10.1182/blood.v92.8.2777 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Identification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Keymeulen, A. V., Brown, D. V., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,488 · see citing works
Every step of the way: integrins in cancer progression and metastasis
Hamidi, H., & Ivaska, J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0038-z · Cited by 1,493 · see citing works
Cooper, J. M., & Giancotti, F. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.007 · Cited by 951 · see citing works
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869 · see citing works
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 769 · see citing works
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721 · see citing works
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685 · see citing works
Self-citationCancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 597 · see citing works
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 508 · see citing works
Exploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H., Schwaiger, M., Weinmüller, M., Räder, A. F. B., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429 · see citing works
Tumor microenvironment and cancer therapy resistance
Sun, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 384 · see citing works
Drug resistance and Cancer stem cells
Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00627-5 · Cited by 334 · see citing works
Patient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 282 · see citing works
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis
Laubli, H. P., & Borsig, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02120 · Cited by 283 · see citing works
The NF-κB Pathway and Cancer Stem Cells
Rinkenbaugh, A. L., & Baldwin, A. S. (2016) · Cells · doi:10.3390/cells5020016 · Cited by 265 · see citing works
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy
Carlson, P., Dasgupta, A., Grzelak, C. A., Kim, J., Barrett, A. S., Coleman, I. M., Shor, R. E., Goddard, E. T., Dai, J., Schweitzer, E. M., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0267-0 · Cited by 251 · see citing works
Self-citationZhang, P., Li, K.-S., Shen, Y.-H., Gao, P.-T., Dong, Z.-R., Cai, J.-B., Zhang, C., Huang, X.-Y., Tian, M.-X., Zq, H., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.324 · Cited by 248 · see citing works
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-Czernilofsky, U., Engle, D. D., Pérez-Mancera, P. A., Coupland, S. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1201 · Cited by 241 · see citing works
Self-citationMurtuza, A., Bulbul, A., Shen, J. P., Keshavarzian, P., Woodward, B. D., Lopez-Diaz, F. J., Lippman, S. M., & Husain, H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1281 · Cited by 226 · see citing works
Self-citationEGFR and NF-κB: partners in cancer
Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 218 · see citing works
PHGDH heterogeneity potentiates cancer cell dissemination and metastasis
Rossi, M., Altea-Manzano, P., Demicco, M., Doglioni, G., Bornes, L., Fukano, M., Vandekeere, A., Cuadros, A. M., Fernández-García, J., Riera-Domingo, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04758-2 · Cited by 213 · see citing works
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W. Q., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 212 · see citing works
Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway
Rapisarda, V., Borghesan, M., Miguela, V., Encheva, V., Snijders, A. P., Lujambio, A., & O’Loghlen, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.012 · Cited by 190 · see citing works
Shen, M., Jiang, Y., Wei, Y., Ell, B. J., Sheng, X., Esposito, M., Kang, J., Hang, X., Zheng, H., Rowicki, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.016 · Cited by 193 · see citing works
Integrins in cancer: Emerging mechanisms and therapeutic opportunities
Liu, F., Wu, Q., Dong, Z., & Liu, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108458 · Cited by 191 · see citing works
METTL1‐m7G‐EGFR/EFEMP1 axis promotes the bladder cancer development
Ying, X., Liu, B., Yuan, Z., Huang, Y., Chen, C., Xu, J., Zhang, H., Qi, D., Yang, S., Lin, S., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.675 · Cited by 188 · see citing works
Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression
Seager, R. J., Hajal, C., Spill, F., Kamm, R. D., & Zaman, M. H. (2017) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/aa7e86 · Cited by 185 · see citing works
Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis
Zhu, Z., Mesci, P., Bernatchez, J. A., Gimple, R. C., Wang, X., Schafer, S. T., Wettersten, H. I., Beck, S., Clark, A. E., Wu, Q., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2019.11.016 · Cited by 184 · see citing works
Self-citationLuo, J., Yao, J., Deng, X., Zheng, X., Jia, M., Wang, Y., Huang, Y., & Zhu, J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0694-6 · Cited by 184 · see citing works
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · see citing works
Basu, S., Cheriyamundath, S., & Ben‐Ze'ev, A. (2018) · F1000Research · doi:10.12688/f1000research.15782.1 · Cited by 175 · see citing works
Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
Alday-Parejo, B., Stupp, R., & Rüegg, C. (2019) · Cancers · doi:10.3390/cancers11070978 · Cited by 175 · see citing works
Pearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lü, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.016 · Cited by 172 · see citing works
Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
Seguin, L., Durandy, M., & Féral, C. C. (2022) · Cancers · doi:10.3390/cancers14071759 · Cited by 174 · see citing works
Self-citationThe paradoxical functions of EGFR during breast cancer progression
Ali, R., & Wendt, M. K. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.42 · Cited by 170 · see citing works
Wu, B., Shi, X., Jiang, M., & Liu, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01748-4 · Cited by 173 · see citing works
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Cosset, E. C., Ilmjärv, S., Dutoit, V., Elliott, K. C., Schalscha, T. V., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G. G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 170 · see citing works
Self-citationFrom transformation to metastasis: deconstructing the extracellular matrix in breast cancer
Kaushik, S., Pickup, M. W., & Weaver, V. M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9650-0 · Cited by 165 · see citing works
Role of p38 MAP kinase in cancer stem cells and metastasis
Kudaravalli, S., den Hollander, P., & Mani, S. A. (2022) · Oncogene · doi:10.1038/s41388-022-02329-3 · Cited by 151 · see citing works
Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150 · see citing works
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0776-6 · Cited by 147 · see citing works
Galectin-3 and cancer stemness
Nangia‐Makker, P., Hogan, V. A., & Raz, A. (2018) · Glycobiology · doi:10.1093/glycob/cwy001 · Cited by 145 · see citing works
The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas
Fedele, M., Cerchia, L., & Chiappetta, G. (2017) · Cancers · doi:10.3390/cancers9100134 · Cited by 141 · see citing works
Wu, X., Cai, J., Zuo, Z., & Li, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108708 · Cited by 142 · see citing works
Prescott, J. A., & Cook, S. J. (2018) · Cells · doi:10.3390/cells7090115 · Cited by 139 · see citing works
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 141 · see citing works
EGFR-mediated autophagy in tumourigenesis and therapeutic resistance
Wu, M., & Zhang, P. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.030 · Cited by 131 · see citing works
Extracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response
Leight, J. L., Drain, A. P., & Weaver, V. M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034431 · Cited by 131 · see citing works
The Biological Functions and Clinical Applications of Integrins in Cancers
Su, C., Li, J., Zhang, L.-L., Wang, H., Wang, F., Tao, Y., Wang, Y., Guo, Q., Li, J., Liu, Y., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.579068 · Cited by 116 · see citing works
Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame
Gentry, L. R., Martin, T. D., Reiner, D. J., & Der, C. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.004 · Cited by 110 · see citing works
Wang, M., Han, J., Marcar, L., Black, J. C., Liu, Q., Li, X., Nagulapalli, K., Sequist, L. V. D., Mak, R. H., Benes, C. H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0808 · Cited by 108 · see citing works
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
Blandin, A.-F., Renner, G., Lehmann, M., Lelong-Rebel, I. H., Martin, S., & Dontenwill, M. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00279 · Cited by 105 · see citing works
Koga, Y., & Ochiai, A. (2019) · Cells · doi:10.3390/cells8050418 · Cited by 107 · see citing works
Nguyen, L. V., Cox, C. L., Eirew, P. D., Knapp, D. J. H. F., Pellacani, D., Kannan, N., Carles, A., Moksa, M., Balani, S., Shah, S. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6871 · Cited by 105 · see citing works
Macropinocytosis: Insights from immunology and cancer
Stow, J. L., Hung, Y., & Wall, A. A. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.06.005 · Cited by 95 · see citing works
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers
Seguin, L., Camargo, M. F., Wettersten, H. I., Kato, S., Desgrosellier, J. S., Schalscha, T. V., Elliott, K. C., Cosset, E. C., Lesperance, J., Weis, S. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0539 · Cited by 102 · see citing works
Self-citationYue, J., Lv, D., Wang, C., Li, L., Zhao, Q., Chen, H., & Xu, L. (2018) · Oncogene · doi:10.1038/s41388-018-0276-2 · Cited by 102 · see citing works
Photodynamic Therapy and the Biophysics of the Tumor Microenvironment
Sorrin, A. J., Ruhi, M. K., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., Huang, H., & Rizvi, I. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13209 · Cited by 101 · see citing works
NF-κB signaling in cancer stem cells: a promising therapeutic target?
Vázquez-Santillán, K., Meléndez-Zajgla, J., Jiménez-Hernández, L., Martinez‐Ruíz, G. U., & Maldonado, V. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0236-6 · Cited by 100 · see citing works
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy
Ebrahimi, N., Abdulwahid, A. R. R., Mansouri, A., Karimi, N., Bostani, R. J., Beiranvand, S., Adelian, S., Khorram, R., Vafadar, R., Hamblin, M. R., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05098-8 · Cited by 98 · see citing works
PI 3K/Akt/ mTOR pathway dual inhibitor BEZ 235 suppresses the stemness of colon cancer stem cells
Chen, J., Shao, R., Li, F., Monteiro, M. J., Liu, J., Xu, Z. P., & Gu, W. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12493 · Cited by 95 · see citing works
Macropinocytosis in Cancer: A Complex Signaling Network
Zhang, Y., & Commisso, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.04.002 · Cited by 94 · see citing works
Novel Galectin-3 Roles in Neurogenesis, Inflammation and Neurological Diseases
Soares, L. C., Al‐Dalahmah, O., Hillis, J. M., Young, C. C., Asbed, I., Sakaguchi, M., O’Neill, E. E., & Szele, F. G. (2021) · Cells · doi:10.3390/cells10113047 · Cited by 94 · see citing works
Integrin αvβ3 Drives Slug Activation and Stemness in the Pregnant and Neoplastic Mammary Gland
Desgrosellier, J. S., Lesperance, J., Seguin, L., Gozo, M. C., Kato, S., Franovic, A., Yebra, M., Shattil, S. J., & Cheresh, D. A. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.06.005 · Cited by 94 · see citing works
Self-citationSeo, H. A., Moeng, S., Sim, S., Kuh, H. J., Choi, S. Y., & Park, J. K. (2019) · Cells · doi:10.3390/cells9010029 · Cited by 93 · see citing works
Camorani, S., Crescenzi, E., Gramanzini, M., Fedele, M., Zannetti, A., & Cerchia, L. (2017) · Scientific Reports · doi:10.1038/srep46659 · Cited by 92 · see citing works
PAKs in Human Cancer Progression
Kumar, R., & Li, D.-Q. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.002 · Cited by 90 · see citing works
LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription
Kang, C. L., Qi, B., Cai, Q., Fu, L., Ying, Y., Tang, C., Zhu, P., Chen, Q. W., Pan, J., Chen, M. H., et al. (2019) · Theranostics · doi:10.7150/thno.32854 · Cited by 89 · see citing works
Integrins regulate stemness in solid tumor: an emerging therapeutic target
Xiong, J., Yan, L., Zou, C., Wang, K., Chen, M., Xu, B., Zhou, Z., & Zhang, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01192-1 · Cited by 89 · see citing works
αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
Vannini, A., Leoni, V., Barboni, C., Sanapo, M., Zaghini, A., Malatesta, P., Campadelli‐Fiume, G., & Gianni, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901931116 · Cited by 88 · see citing works
The challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials
Gu, Y., Dong, B., Xu, H., Qiu, Z., Zhang, J., Zhang, M., Liu, H., Pang, X., & Cui, Y. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106694 · Cited by 87 · see citing works
Cancer stem cell drugs target K-ras signaling in a stemness context
Najumudeen, A. K., Jaiswal, A., Lectez, B. L. P., Oetken-Lindholm, C., Guzmán, C., Siljamäki, E., Posada, I. M. D., Lacey, E., Aittokallio, T. A., & Abankwa, D. (2016) · Oncogene · doi:10.1038/onc.2016.59 · Cited by 86 · see citing works
Kwon, Y.-J., Petrie, K. R., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0980-t · Cited by 83 · see citing works
Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer
Silva, E. C. D., Dontenwill, M., Choulier, L., & Lehmann, M. (2019) · Cancers · doi:10.3390/cancers11050692 · Cited by 81 · see citing works
Collective cancer invasion forms an integrin-dependent radioresistant niche
Haeger, A., Alexander, S., Vullings, M., Kaiser, F. M. P., Hulsbergen-Veelken, C. A. R., Flucke, U. E., Koehl, G. E., Hirschberg, M., Flentje, M. P., Hoffman, R. M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181184 · Cited by 81 · see citing works
Liang, S.-Q., Marti, T. M., Dorn, P., Froment, L., Hall, S., Berezowska, S., Kocher, G. J., Schmid, R. A., & Peng, R. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.195 · Cited by 79 · see citing works
Qiu, S., Deng, L., Liao, X., Nie, L., Qi, F., Jin, K., Tu, X., Zheng, X. S., Li, J., Liu, L., et al. (2019) · Cancer Science · doi:10.1111/cas.14078 · Cited by 78 · see citing works
ITGB3/CD61: a hub modulator and target in the tumor microenvironment.
Zhu, C., Kong, Z., Wang, B., Cheng, W., Wu, A., & Meng, X. (2019) · Europe PMC (PubMed Central) · Cited by 76 · see citing works
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 71 · see citing works
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop
Shi, L., Wang, Y., Lü, Z., Zhang, H., Zhuang, N., Wang, B., Song, Z., Chen, G., Huang, C., Xu, D., et al. (2016) · Oncogene · doi:10.1038/onc.2016.332 · Cited by 70 · see citing works
β1 and β3 integrins in breast, prostate and pancreatic cancer: A novel implication (Review)
Pan, B., Guo, J., Liao, Q., & Zhao, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8076 · Cited by 69 · see citing works
A cell–ECM screening method to predict breast cancer metastasis
Barney, L. E., Dandley, E. C., Jansen, L. E., Reich, N. G., Mercurio, A. M., & Peyton, S. R. (2014) · Integrative Biology · doi:10.1039/c4ib00218k · Cited by 69 · see citing works
Precision Oncology: Between Vaguely Right and Precisely Wrong
Brock, A., & Huang, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0448 · Cited by 67 · see citing works
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Echavidre, W., Picco, V., Faraggi, M., & Montemagno, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051053 · Cited by 66 · see citing works
Zhang, K., Myllymäki, S.-M., Gao, P. H., Devarajan, R., Kytölä, V., Nykter, M., Wei, G., & Manninen, A. (2017) · Oncogene · doi:10.1038/onc.2017.177 · Cited by 66 · see citing works
Tang, Y.-A., Chen, C.-H., Sun, H. S., Cheng, C.-P., Tseng, V. S. M., Hsu, H., Su, W., Lai, W., & Wang, Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv024 · Cited by 65 · see citing works
Zhong, C., Tao, B., Tang, F., Yang, X., Peng, T., You, J., Xia, K., Xia, X., Chen, L., & Peng, L. (2020) · Theranostics · doi:10.7150/thno.50613 · Cited by 64 · see citing works
Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Lambert, A. W., Wong, C. K., Ozturk, S., Papageorgis, P., Raghunathan, R., Alekseyev, Y. O., Gower, A. C., Reinhard, B. M., Abdolmaleky, H. M., & Thiagalingam, S. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0079 · Cited by 63 · see citing works
Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Candelotti, E., Vito, P. D., Ahmed, R. G., Luly, P., Davis, P. J., Pedersen, J. Z., Lin, H., & Incerpi, S. (2015) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152221501150710131534 · Cited by 61 · see citing works
Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
Σπέλλα, Μ., Lilis, I., Pepe, M. A. A., Chen, Y., Armaka, M., Lamort, A., Zazara, D. E., Roumelioti, F., Vreka, M., Kanellakis, N. I., et al. (2019) · eLife · doi:10.7554/elife.45571 · Cited by 57 · see citing works
Functional and clinical characteristics of focal adhesion kinases in cancer progression
Zhang, Z., Li, J., Jiao, S., Han, G., Zhu, J., & Liu, T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1040311 · Cited by 62 · see citing works
Pleural involvement in lung cancer.
Agalioti, T., Giannou, A. D., & Stathopoulos, G. T. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2015.04.23 · Cited by 61 · see citing works
Carino, A., Graziosi, L., D’Amore, C., Cipriani, S., Marchianò, S., Marino, E., Zampella, A., Rende, M., Mosci, P., Distrutti, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10477 · Cited by 61 · see citing works
The roles of integrins in cancer
Valdembri, D., & Serini, G. (2021) · Faculty Reviews · doi:10.12703/r/10-45 · Cited by 60 · see citing works
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zhang, Z., Zhang, H., Liao, X., & Tsai, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147676 · Cited by 62 · see citing works
Ral signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58 · see citing works
The Future of Patient-Derived Tumor Xenografts in Cancer Treatment
Sia, D., Moeini, A., Labgaa, I., & Villanueva, A. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.102 · Cited by 58 · see citing works
Cazzanelli, G., Pereira, F. D. S., Alves, S., Francisco, R., Azevedo, L., Carvalho, P. D., Almeida, A. F., Côrte‐Real, M., Oliveira, M. J., Lucas, C., et al. (2018) · Cells · doi:10.3390/cells7020014 · Cited by 59 · see citing works
The pervasiveness of macropinocytosis in oncological malignancies
Commisso, C. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0153 · Cited by 56 · see citing works
Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior
Kumar, V. E., Nambiar, R., Souza, C. D., Nguyen, A. D., CHIEN, J. R., & Lam, K. S. (2022) · Cells · doi:10.3390/cells11091403 · Cited by 59 · see citing works
- Authors
- Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., Cascone, T., Diao, L., Wang, J., Wistuba, I. I., Heymach, J. V., Lippman, S. M., Desgrosellier, J. S., Anand, S., Weis, S. M., & Cheresh, D. A.
- Affiliations
- University of California San Diego (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Cheresh, David A.
- ORCID
- Venue
- Nature Cell Biology
- Published
- 2014-04-20
- Volume
- 16
- Issue
- 5
- Pages
- 457-468
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC4105198
- OpenAlex
- W2029572050
- Cited by
- 374
- References
- 59
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 22 · 2023: 32 · 2022: 27 · 2021: 36 · 2020: 35 · 2019: 41 · 2018: 28 · 2017: 33 · 2016: 40 · 2015: 34 · 2014: 14
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- National Institutes of Health
- U.S. Public Health Service (R3750286)
- National Heart, Lung, and Blood Institute (HL 57900, R00HL112962, P01HL057900)
- National Cancer Institute (CA-45726, R01CA045726, CA155620, R01CA155620, R37CA050286, R01CA168692, CA168692, P30CA023100, T32CA121938, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- integrin αvβ3, KRAS, RalB, erlotinib resistance, cancer stemness, cancer stem cells, NF-κB activation, TBK1, bortezomib, anchorage-independent growth, self-renewal, tumor initiation, lung cancer, breast cancer, pancreatic cancer
- MeSH terms
- Erlotinib Hydrochloride, Animals, Female, Humans, Lung Neoplasms, Mice, Nude, Phenotype, Proto-Oncogene Proteins, Quinazolines, Time Factors, Transfection, Tumor Cells, Cultured, Neoplastic Stem Cells, Signal Transduction, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Clinical Trials, Phase II as Topic, Protein Serine-Threonine Kinases, ras Proteins, Spheroids, Cellular, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-rel, ral GTP-Binding Proteins, Xenograft Model Antitumor Assays, RNA Interference, Integrin alphaVbeta3, Integrin beta3, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Cell Proliferation, Mice, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
